Trial reportMedicine2025
Weizmannia coagulans BC01 supplementation improved functional constipation by regulating gut microbiota: A randomized, placebo-controlled, clinical study.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Constipation in Older Adults: Pathophysiology, Clinical Impact, and Management Strategies.Geriatrics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFunctional constipation is a prevalent gastrointestinal disease that remains challenging to cure. Probiotic is a promising way to treat functional constipation. Weizmannia coagulans BC01, a genetically and phenotypically safe probiotic strain, has the potential ability to improve constipation symptoms.
methodsWe mainly investigated the effects of W coagulans BC01 (BC01) in the management of functional constipation and associated gastrointestinal symptoms in a randomized, double-blind, placebo-controlled trial. A total of 113 patients diagnosed with functional constipation (following Rome IV criteria) were randomly divided into BC01 (n = 79; received BC01 powder; 5 × 109 CFU/d) and placebo (n = 34; received placebo material) groups. Constipation symptoms were evaluated by the ROME IV criteria and evacuation diaries. The clinical improvement was evaluated using the Cleveland Scores, the Bristol, and the Gastrointestinal Quality of Life Index. Short-chain fatty acids were detected by reverse transcriptase polymerase chain reaction. Fecal microbiota was analyzed by 16S rRNA gene sequencing.
resultsAfter 21 days of treatment, the values of Bristol and Gastrointestinal Quality of Life Index were significantly increased by BC01 supplementation, and the Cleveland scores was decreased in patients with functional constipation. Besides, the contents of acetic acid and isobutyric acid significantly increased by treated with BC01. The disorder gut microbiota in patients with functional constipation was also reshaped by BC01, resulting in higher abundance of Bacteroides, Bifidobacterium, and Roseburia, and lower abundance of Firmicutes, Proteobacteria, and Blautia. No adverse events were observed throughout the trial period.
conclusionCurrent evidence supports the use of BC01 as a therapeutic option for managing functional constipation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.